Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
- Author
- BURANT, Charles F1
[1] Department of Internal Medicine and the Michigan Metabolomics and Obesity Center, University of Michigan, Ann Arbor, Michigan, United States - Conference title
- Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)
- Conference name
- CODHy World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (4 ; Barcelona 2012-11-08)
- Author (monograph)
- RAZ, Itamar (Editor)1 ; DEL PRATO, Stefano (Editor)2
[1] Diabetes Unit, Department of Medicine, Hadassah University Hospital, Ein-Karem, Jerusalem, Israel
[2] Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy - Source
Diabetes care. 2013, Vol 36 ; S175-S179 ; SUP2 ; ref : 55 ref
- CODEN
- DICAD2
- ISSN
- 0149-5992
- Scientific domain
- Endocrinology; Nutrition, obesity, metabolic disorders
- Publisher
- American Diabetes Association, Alexandria, VA
- Publication country
- United States
- Document type
- Conference Paper
- Language
- English
- Keyword (fr)
- Activation Diabète de type 2 Endocrinologie Homme Maladie métabolique Médicament ciblé Nutrition Traitement Endocrinopathie
- Keyword (en)
- Activation Type 2 diabetes Endocrinology Human Metabolic diseases Targeted drug Nutrition Treatment Endocrinopathy
- Keyword (es)
- Activación Diabetes de tipo 2 Endocrinología Hombre Metabolismo patología Medicamento dirigido Nutrición Tratamiento Endocrinopatía
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B30 Public health. Hygiene-occupational medicine / 002B30A Public health. Hygiene / 002B30A11 Miscellaneous
- Discipline
- Endocrinopathies Metabolic diseases Public health. Hygiene-occupational medicine
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27696519
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2337/dcS13-2037 
https://dx.doi.org/10.2337/dcS13-2037
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:9:\"S175-S179\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"BURANT\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Charles F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:112:\"Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)\";s:8:\"\u0000*\u0000title\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:9:\"S175-S179\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"BURANT\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Charles F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:112:\"Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)\";s:8:\"\u0000*\u0000title\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:9:\"S175-S179\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"BURANT\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Charles F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:112:\"Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)\";s:8:\"\u0000*\u0000title\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:9:\"S175-S179\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"BURANT\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Charles F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:112:\"Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)\";s:8:\"\u0000*\u0000title\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:18:\"10.2337\/dcS13-2037\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Diabetes care\";s:9:\"\u0000*\u0000stitle\";s:13:\"Diabetes care\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"36\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:9:\"S175-S179\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-5992\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"BURANT\";s:10:\"\u0000*\u0000aufirst\";s:9:\"Charles F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:0:{}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DICAD2\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:4:\"SUP2\";s:9:\"\u0000*\u0000btitle\";s:112:\"Proceedings of the 4th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy)\";s:8:\"\u0000*\u0000title\";s:80:\"Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:29:\"American Diabetes Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
